CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D012213: Rheumatic Fever NIH

(Synonyms: Rheumatic Fever)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug155 COVID-19 diagnostic test Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D003095 Collagen Diseases NIH 0.71
D001327 Autoimmune Diseases NIH 0.71
D012216 Rheumatic Diseases NIH 0.71

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases : a Retrospective Multicenter Observational Study

Since December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge. In France, while the first cases were reported in January, more than 20 000 cases were confirmed at end of March. Early estimations from epidemiological data seem to show that 18-20% of patients with confirmed covid-19 are admitted in an intensive care unit (ICU). Patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases are susceptible to severe covid-19 (i.e ICU) due to the specific therapeutic management of their illness (corticosteroid, immunosuppressive and immunomodulatory drugs,..). No data are available for this particular population in France. This retrospective multicentre observational study aims to evaluate the frequency of severe forms of covid-19 and risk factors associated with specific outcomes in covid-19 in patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases.

NCT04353609 Sars-CoV2 Chronic Inflammatory Rheumatism Autoimmune Diseases
MeSH:Rheumatic Fever Rheumatic Diseases Collagen Diseases Autoimmune Diseases
HPO:Autoimmunity

Primary Outcomes

Measure: Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death

Time: From Baseline up to Day 21 after first symptoms of covid-19

Secondary Outcomes

Measure: Proportion of patients who die from a severe form of covid-19

Time: From Baseline up to Day 21 after first symptoms of covid-19

Measure: Proportion of patients who present an history of diabetes according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg/cm2)

Time: At the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of Asthma according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of Hypertension according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of cardiac disease according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of stroke according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

Measure: Proportion of patients who present an history of cancer according to medical records

Time: Before the set-up of first symptoms of covid-19 (Baseline visit)


HPO Nodes